Keynote B59
Phase 1/2 Recruiting
317 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
LITESPARK-033
Phase 3 Recruiting
904 enrolled
STELLAR-002
Phase 1 Recruiting
1,314 enrolled
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Phase 1 Recruiting
30 enrolled
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1 Recruiting
125 enrolled
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Phase 1 Recruiting
307 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Phase 1/2 Recruiting
234 enrolled
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Phase 1/2 Recruiting
75 enrolled
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Phase 1 Recruiting
70 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Phase 1/2 Recruiting
224 enrolled
ARC-20
Phase 1 Recruiting
362 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
DP-04
Recruiting
100 enrolled
MK-3475-03C
Phase 1/2 Recruiting
140 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
450 enrolled
BASECAMP-1
Recruiting
200 enrolled
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
Phase 1 Recruiting
174 enrolled
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Phase 1 Recruiting
60 enrolled
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 Recruiting
280 enrolled
A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
250 enrolled
Sapu003 in Advanced mTOR-sensitive Solid Tumors
Phase 1 Recruiting
27 enrolled
A Study of HC-7366 in Combination With Belzutifan (WELIREGâ„¢) in Patients With Renal Cell Carcinoma
Phase 1 Recruiting
80 enrolled
FIT-001
Phase 1 Recruiting
300 enrolled
ELEPHAS-02
Recruiting
416 enrolled
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 Recruiting
248 enrolled
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
158 enrolled
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Phase 1 Recruiting
130 enrolled
BrILliance
Phase 1/2 Recruiting
240 enrolled
LB-LR1109
Phase 1 Recruiting
76 enrolled
PRCC
Recruiting
150 enrolled
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Phase 1/2 Recruiting
345 enrolled
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
270 enrolled
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Phase 1 Recruiting
130 enrolled
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Phase 1 Recruiting
90 enrolled
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Phase 1 Recruiting
67 enrolled
CARAT
Recruiting
1,930 enrolled
ModiFY
Phase 1/2 Recruiting
168 enrolled
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 Recruiting
126 enrolled
TraveraRTGx
Recruiting
200 enrolled
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
76 enrolled
A Multicenter Study of RUS NE
Phase NA Recruiting
204 enrolled
DENALI-1
Phase 1/2 Recruiting
240 enrolled
ORACLE
Recruiting
2,020 enrolled
ABILITY-1
Phase 1/2 Recruiting
115 enrolled
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Phase 1/2 Recruiting
170 enrolled